| Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian … O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ... Cancer discovery 7 (9), 984-998, 2017 | 356 | 2017 |
| Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies GY Ho, N Woodward, JIG Coward Critical reviews in oncology/hematology 102, 37-46, 2016 | 298 | 2016 |
| Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma O Kondrashova, M Topp, K Nesic, E Lieschke, GY Ho, MI Harrell, ... Nature communications 9 (1), 3970, 2018 | 225 | 2018 |
| The molecular origin and taxonomy of mucinous ovarian carcinoma D Cheasley, MJ Wakefield, GL Ryland, PE Allan, K Alsop, ... Nature communications 10 (1), 3935, 2019 | 136 | 2019 |
| A community-based model of rapid autopsy in end-stage cancer patients K Alsop, H Thorne, S Sandhu, A Hamilton, C Mintoff, E Christie, O Spruyt, ... Nature biotechnology 34 (10), 1010-1014, 2016 | 83 | 2016 |
| Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma K Nesic, O Kondrashova, RM Hurley, CD McGehee, CJ Vandenberg, ... Cancer research 81 (18), 4709-4722, 2021 | 48 | 2021 |
| The role of interleukin-6 in malignant mesothelioma SNA Rahim, GY Ho, JIG Coward Translational lung cancer research 4 (1), 55, 2015 | 40 | 2015 |
| T-Cell receptor therapy in the treatment of ovarian cancer: A mini review JWY Wu, S Dand, L Doig, AT Papenfuss, CL Scott, G Ho, JD Ooi Frontiers in immunology 12, 672502, 2021 | 38 | 2021 |
| Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses EY Kang, D Cheasley, C LePage, MJ Wakefield, M da Cunha Torres, ... Modern Pathology 34 (1), 194-206, 2021 | 23 | 2021 |
| Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: non-consecutive case series and review of the literature S David, G Ho, D Day, M Harris, J Tan, S Goel, GG Hanna, R Srivastava, ... Translational Oncology 14 (1), 100939, 2021 | 20 | 2021 |
| Interferon-ε is a tumour suppressor and restricts ovarian cancer ZRC Marks, NK Campbell, NE Mangan, CJ Vandenberg, LJ Gearing, ... Nature 620 (7976), 1063-1070, 2023 | 14 | 2023 |
| Suppression of the ABCA1 cholesterol transporter impairs the growth and migration of epithelial ovarian cancer J Gao, MS Jung, RT Williams, D Hui, AJ Russell, AJ Naim, A Kamili, ... Cancers 14 (8), 1878, 2022 | 13 | 2022 |
| ABCC4/MRP4 contributes to the aggressiveness of Myc‐associated epithelial ovarian cancer M Jung, J Gao, L Cheung, A Bongers, K Somers, M Clifton, EE Ramsay, ... International Journal of Cancer 147 (8), 2225-2238, 2020 | 10 | 2020 |
| NETosis as an oncologic therapeutic target: a mini review S Jaboury, K Wang, KM O’Sullivan, JD Ooi, GY Ho Frontiers in immunology 14, 1170603, 2023 | 7 | 2023 |
| Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 2018; 9: 3970 O Kondrashova, M Topp, K Nesic, E Lieschke, GY Ho, MI Harrell PUBMED, 0 | 7 | |
| Epithelial-to-mesenchymal transition supports ovarian Carcinosarcoma tumorigenesis and confers sensitivity to microtubule targeting with Eribulin GY Ho, EL Kyran, J Bedo, MJ Wakefield, DP Ennis, HB Mirza, ... Cancer Research 82 (23), 4457-4473, 2022 | 6 | 2022 |
| Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors C Grohmann, F Walker, M Devlin, MX Luo, AC Chüeh, J Doherty, ... Cell Death & Disease 12 (3), 268, 2021 | 3 | 2021 |
| Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1−/− mice JT Low, GY Ho, M Scott, CW Tan, L Whitehead, K Barber, HYK Yip, ... Cell Death & Disease 12 (12), 1091, 2021 | 2 | 2021 |
| Ovarian Cancer-Updates in Tumour Biology and Therapeutics GY Ho, K Webber | 2 | 2021 |
| Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer K Lin, AV Tinker, O Kondrashova, G Ho, M Wakefield, RL Coleman, ... European Journal of Cancer 1 (69), S13, 2016 | 2 | 2016 |
